278112
Three year trends in the use of emerging tobacco products
Methods: In 2010-2012, we applied a mixed-mode survey to obtain annual, representative samples of US adults.
Results: In weighted analysis, lifetime prevalence of snus use (5.1% to 6.5%) and water pipe (8.8% to 9.9%) did not significantly change from 2011-12. Lifetime prevalence of electronic cigarettes increased from 1.8% to 10.8%, p <.001. In 2012, daily smokers (44.8%) and nondaily smokers (24.5%) were the most likely to have tried electronic cigarettes, compared to former smokers (7.5%) and never smokers (1.7%). Younger (12.8%) and middle aged adults (13.4%) compared to older adults (2.4%) and those without a high school degree (10.9% vs 7.4%) were more likely to have tried electronic cigarettes (p<.05 for all comparisons). In multivariable analysis, current daily (OR=53.3 , 95% CI = 34.0–83.6), nondaily (20.2, 11.0–37.2), and former smoking status (6.6, 4.1–10.5) remained significant, as did young (7.2, 3.5–15.0) and middle aged adults (6.7, 3.9-11.3).
Conclusion: Use of emerging tobacco products raises concerns about nonsmokers being at risk for nicotine dependence, current smokers maintaining their dependence, and the impact of poly-tobacco use. Greater awareness of emerging tobacco product prevalence and the high risk demographic user groups will inform efforts to determine appropriate public health policy and regulatory action.
Social and behavioral sciences
Learning Objectives:
Describe the three year trend in use of emerging tobacco products.
Keywords: Tobacco Policy, Tobacco Control
Qualified on the content I am responsible for because: I direct the National Social Climate Survey of Tobacco Control through a cooperative project with the Social Science Research Center and the American Academy of Pediatrics’ Julius B. Richmond Center. I also serves as Principal Investigator for the Surveillance and Evaluation Services grant for the Mississippi State Department of Health’s Office of Tobacco Control.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.